Figure 2. Effects of hCAR ligands on the anti-tumor efficacy of paclitaxel in six different human lung cancer cells.

Cell viability after 48-agonist Androstenol in combination with Paclitaxel. CITCO enhances paclitaxel cytotoxicity significantly in five of six cell lines (* p<0.05 – Two way ANOVA followed by Tukey's multiple comparison test for treatment effect). On the other hand, androstenol in combination with paclitaxel has no effect in comparison to paclitaxel-treated cells.